Is Basilea likely to get a buyout offer?

Shares of Basilea Pharmaceutica shot up as speculation about a possible takeover attempts heats up. Basilea recently won a $130 million arbitration award from J&J, which was held responsible for botching clinical trial work on ceftobiprole. The anti-infective was shot down by regulators in Europe and the U.S. after they determined that the data presented was unreliable. Now the biotech's low market value, pipeline of new anti-infectives and cash in the bank has made it an attractive takeover target, according to some analysts. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.